INVO Fertility, Inc. (NASDAQ: IVF) Files Amendment No. 1 to Annual Report on Form 10-K
Key Points and Investor Insights
INVO Fertility, Inc. has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This filing, submitted on June 12, 2026, comes as an update to the original report previously filed on June 2, 2026. Below are the critical highlights from the amendment, with a focus on matters relevant and potentially price-sensitive for shareholders.
1. Nature and Scope of the Amendment
- Purpose of Amendment: The amendment was filed to update disclosures in Part III, specifically related to Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, and related matters. It replaces prior references to the incorporation of the company’s proxy statement into Part III.
- No New Financial Statements: No financial statements or supplemental data are included in this amendment. The amendment does not update disclosures from the original filing except as specifically noted.
- Certifications Updated: The amendment includes currently-dated certifications from the Principal Executive Officer and Principal Financial Officer in accordance with SEC rules, omitting certain paragraphs as no financial statements are presented.
2. Corporate Governance and Insider Trading
- Board and Audit Committee: The Audit Committee reviewed the effectiveness of internal controls, risk management, financial statements, and the qualifications and independence of external auditors. It met six times in 2025.
- Insider Trading Policy: The company has an adopted Insider Trading Policy for directors, officers, and employees, promoting compliance with laws and market rules.
- Equity Grant Timing: INVO Fertility disclosed that it does not have policies regarding the timing of equity awards relative to the release of material nonpublic information. In 2025, no equity awards were made to executive officers during blackout periods surrounding key filings.
- Section 16(a) Compliance: All required filings by directors and officers were made on time except for a single late Form 4 by CEO Steven Shum.
3. Executive Compensation and Pay Versus Performance
- Summary Compensation: The amendment presents detailed tables on executive compensation, including salary, option awards, and stock awards for named executive officers. For 2025, CEO Steven Shum’s compensation included a salary and unvested options, with the value of unvested options to be marked to market as they vest.
- No Compensatory Grants Tied to Material Nonpublic Information: No equity awards were made based on undisclosed material information.
- Pay Versus Performance Disclosure: Required under Dodd-Frank, the company included a pay vs. performance disclosure, showing the relationship between executive compensation and financial performance metrics, including total shareholder return and net loss.
- Restatement of Previous Financials: The company identified and corrected multiple material errors in its previous financial statements for 2025, including issues related to revenue recognition, convertible debenture accounting, gain recognition, warrant classification, and debt extinguishment. The restatement was filed with the SEC on June 2, 2026.
4. Shareholder and Equity Information
- Common Stock Outstanding: As of June 12, 2026, there were 1,786,035 shares of common stock outstanding.
- Equity Compensation Plans: As of December 31, 2025, 9,123 securities were to be issued upon exercise of outstanding options, with a weighted average exercise price of \$563.91, and 872 securities remained available for future issuance under approved plans. No equity compensation plans not approved by shareholders exist.
- Ownership of Securities: No individual shareholder or group is known to beneficially own more than 5% of the company’s outstanding common stock. Officers and directors own small amounts, including stock options that are either vested or will vest within 60 days.
5. Audit and Accounting
- Audit Fees: Audit fees cover the annual audit and quarterly reviews. Audit-Related Fees include assurance services for compliance and transaction support, such as comfort letters and acquisition audits.
- Restatement Impact: The financial restatement, due to numerous accounting errors, could affect investor confidence and has potential implications for share value, especially given the nature and breadth of the corrections.
6. Certifications and Compliance
- Sarbanes-Oxley Certifications: Both the CEO and CFO certified the accuracy of the filing under Section 302 of the Sarbanes-Oxley Act, confirming the absence of any untrue statements or omissions of material fact.
- Clawback Policy: The company has a clawback policy filed as exhibit 97.1, addressing potential recovery of incentive compensation in the event of restatements or misconduct.
Potentially Price-Sensitive and Noteworthy Items
- Restatement of Financial Statements: The restatement of prior-year financials for multiple material errors is a critical disclosure that may impact investor sentiment and share price.
- No Major Shareholder Concentration: The lack of 5%+ shareholders suggests a widely dispersed ownership, potentially affecting liquidity and governance dynamics.
- Limited Equity Awards and Executive Ownership: Minimal insider ownership and no recent equity awards tied to material events may be relevant for those assessing alignment of management and shareholder interests.
- Absence of New Financials: The amendment does not update the company’s financial position or results beyond previously filed statements, signaling that investors should refer to the original 10-K for financial analysis.
Conclusion
The Amendment No. 1 to INVO Fertility’s 10-K primarily addresses governance and compliance matters, with the most significant development being the restatement of the company’s 2025 financial statements due to multiple accounting errors. Investors should be aware of the implications of these restatements as they may impact the company’s credibility, compliance standing, and potentially its share price. No new financial or operating results are provided in this amendment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should carefully review all official filings and conduct their own due diligence before making investment decisions. The information herein is based solely on the company’s SEC filing and may not include all material information relevant to an investment decision.
